Barclays’s Aurinia Pharmaceuticals AUPH Stock Holding History
Bought
Maintained
Sold
Other funds holding AUPH
Barclays's AUPH Position: Q3 2026 in Review
Barclays increased its Aurinia Pharmaceuticals (AUPH) stake by 119% in Q3 2026, buying an estimated $527K and bringing the position to 60,952 shares worth $987K. The position accounts for ﹤0.01% of the portfolio, ranked #3060.
Barclays first reported a position in AUPH in Q2 2017 and has held it in 35 quarters since. The position peaked at $13.2M in Q3 2021. 277 funds tracked by Wall St. Rank hold AUPH as of Q3 2026.
- Barclays held 60,952 shares of Aurinia Pharmaceuticals worth $987K as of Q3 2026.
- Barclays bought 33,060 Aurinia Pharmaceuticals shares in Q3 2026, an estimated $527K.
- Aurinia Pharmaceuticals made up ﹤0.01% of Barclays's portfolio in Q3 2026, its #3060 holding.
- Barclays first reported a position in Aurinia Pharmaceuticals in Q2 2017 and has held it in 35 quarters since.
- Barclays's Aurinia Pharmaceuticals position peaked at $13.2M in Q3 2021.
- 277 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q3 2026.
Based on Barclays's 13F filing for Q3 2026, filed 6 Nov 2026.